Fig. 1.

Pretreatment of mice with CCL19 plasmid promotes HBV clearance in vivo. a Establishment of CCL19 over expression, CCR7 knockdown and HBV chronic mouse models by H.I. and schedule. Levels of serum HBsAg (b), HBeAg (c) and HBsAb (f) were detected by ELISA. d The rates of serum HBsAg-positive mice in the three CHB mouse models. e Copies of intrahepatic HBV DNA in the three CHB mouse models detected by real-time PCR. g Expression of serum CCL19 mRNA in the three CHB mouse models detected by real-time RT-PCR. h Staining HBc-positive hepatocytes of three CHB mouse models at 4 wpi by IHC assay. Quantification of HBc⁺ cells in five high-power fields for each mouse. The data are presented as the means ± SEMs. i Comparison of the number of HBc-positive hepatocytes. Five to seven mice were analyzed per group, and at least two independent experiments were performed. Significant differences between the groups are indicated: ***p < 0.001, NS not significant